These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36174821)

  • 1. Disopyramide is a safe and effective treatment for children with obstructive hypertrophic cardiomyopathy.
    Topriceanu CC; Field E; Boleti O; Cervi E; Kaski JP; Norrish G
    Int J Cardiol; 2023 Jan; 371():523-525. PubMed ID: 36174821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Markers of responsiveness to disopyramide in patients with hypertrophic cardiomyopathy.
    Habib M; Hoss S; Bruchal-Garbicz B; Chan RH; Rakowski H; Williams L; Adler A
    Int J Cardiol; 2019 Dec; 297():75-82. PubMed ID: 31615649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disopyramide use in infants and children with hypertrophic cardiomyopathy.
    O'Connor MJ; Miller K; Shaddy RE; Lin KY; Hanna BD; Ravishankar C; Rossano JW
    Cardiol Young; 2018 Apr; 28(4):530-535. PubMed ID: 29513203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy: a comparison of flecainide and disopyramide.
    Haruki S; Minami Y; Suzuki A; Hagiwara N
    Heart Vessels; 2015 Sep; 30(5):604-10. PubMed ID: 24917414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paradoxical response to exercise in asymptomatic hypertrophic cardiomyopathy: a new description of outflow tract obstruction dynamics.
    Lafitte S; Reant P; Touche C; Pillois X; Dijos M; Arsac F; Peyrou J; Montaudon M; Ritter P; Roudaut R; Demaria A
    J Am Coll Cardiol; 2013 Aug; 62(9):842-50. PubMed ID: 23810875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long mitral valve leaflets determine left ventricular outflow tract obstruction during exercise in hypertrophic cardiomyopathy.
    Henein M; Arvidsson S; Pilebro B; Backman C; Mörner S; Lindqvist P
    Int J Cardiol; 2016 Jun; 212():47-53. PubMed ID: 27031819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Beneficial effects of disopyramide on left ventricular outflow obstruction in a case of hypertrophic obstructive cardiomyopathy].
    Terrosu P; Franceschino V; Contini GM; Dore L; Ibba GV
    G Ital Cardiol; 1984 Jan; 14(1):63-6. PubMed ID: 6538527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug.
    Verlinden NJ; Coons JC
    Pharmacotherapy; 2015 Dec; 35(12):1164-72. PubMed ID: 26684556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisoprolol for treatment of symptomatic patients with obstructive hypertrophic cardiomyopathy. The BASIC (bisoprolol AS therapy in hypertrophic cardiomyopathy) study.
    Monda E; Lioncino M; Palmiero G; Franco F; Rubino M; Cirillo A; Verrillo F; Fusco A; Caiazza M; Mazzella M; Moscarella E; Dongiglio F; Sepe J; Pacileo G; Calabrò P; Limongelli G
    Int J Cardiol; 2022 May; 354():22-28. PubMed ID: 35278578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of mitral valve leaflet length and septal wall thickness to outflow tract obstruction in patients with hypertrophic cardiomyopathy.
    Morant K; Mikami Y; Nevis I; McCarty D; Stirrat J; Scholl D; Rajchl M; Giannoccaro P; Kolman L; Heydari B; Lydell C; Howarth A; Grant A; White JA
    Int J Cardiovasc Imaging; 2017 Aug; 33(8):1201-1211. PubMed ID: 28391581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spatial relationship between mitral valve and ventricular septum assessed by resting echocardiography to diagnose left ventricular outflow tract obstruction in hypertrophic cardiomyopathy.
    Verheyen N; Batzner A; Zach D; Zirlik A; Gerull B; Frantz S; Maack C; Störk S; Seggewiss H; Morbach C
    Eur Heart J Cardiovasc Imaging; 2023 May; 24(6):710-718. PubMed ID: 36841935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy.
    Matsubara H; Nakatani S; Nagata S; Ishikura F; Katagiri Y; Ohe T; Miyatake K
    J Am Coll Cardiol; 1995 Sep; 26(3):768-75. PubMed ID: 7642872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left ventricular outflow tract pressure gradient changes after carvedilol-disopyramide cotherapy in a cat with hypertrophic obstructive cardiomyopathy.
    Hori Y; Fujimoto E; Nishikawa Y; Nakamura T
    J Vet Cardiol; 2020 Jun; 29():40-46. PubMed ID: 32464577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral disopyramide for the acute treatment of severe outflow obstruction in hypertrophic cardiomyopathy in the ICU setting.
    Sirak TE; Sherrid MV
    Chest; 2008 May; 133(5):1243-6. PubMed ID: 18460523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy.
    Shah JS; Esteban MT; Thaman R; Sharma R; Mist B; Pantazis A; Ward D; Kohli SK; Page SP; Demetrescu C; Sevdalis E; Keren A; Pellerin D; McKenna WJ; Elliott PM
    Heart; 2008 Oct; 94(10):1288-94. PubMed ID: 18032461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Negative ionotropic agents for the treatment of left ventricular outflow tract obstruction due to sigmoid septum and concentric left ventricular hypertrophy.
    Ranasinghe I; Yeoh T; Yiannikas J
    Heart Lung Circ; 2011 Sep; 20(9):579-86. PubMed ID: 21684204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy.
    Fananapazir L; Epstein ND; Curiel RV; Panza JA; Tripodi D; McAreavey D
    Circulation; 1994 Dec; 90(6):2731-42. PubMed ID: 7994815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mid-term outcomes of biventricular obstruction and left ventricular outflow tract obstruction after surgery correction in child and adolescent patients with hypertrophic cardiomyopathy.
    Zhai S; Xu H; Fan C; Yang Y; Hang F; Guo X; Wang H; Duan F; Yan J
    PLoS One; 2018; 13(2):e0192218. PubMed ID: 29408870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of mitral regurgitation in patients with hypertrophic cardiomyopathy using aortic and pulmonary flow data: impacts of left ventricular outflow tract obstruction and different left ventricular segmentation methods.
    Śpiewak M; Kłopotowski M; Gawor M; Kubik A; Kowalik E; Miłosz-Wieczorek B; Dąbrowski M; Werys K; Mazurkiewicz Ł; Kożuch K; Polańska-Skrzypczyk M; Petryka-Mazurkiewicz J; Klisiewicz A; Bilińska ZT; Grzybowski J; Witkowski A; Marczak M
    J Cardiovasc Magn Reson; 2017 Dec; 19(1):105. PubMed ID: 29268761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Left ventricular basal muscle bundle in hypertrophic cardiomyopathy: insights into the mechanism of left ventricular outflow tract obstruction.
    Xiao M; Nie C; Wang J; Zhu C; Sun X; Zhu Z; Wang H; Wang S
    Eur Heart J Cardiovasc Imaging; 2022 Jul; 23(8):1018-1026. PubMed ID: 34718482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.